[1] Burillo-Sanz S, Montes-Cano MA, García-Lozano JR, Ortiz-Fernández L, Ortego-Centeno N, García-Hernández FJ. Mutational profile of rare variants in inflammasome-related genes in Behçet disease: A Next Generation Sequencing approach. Sci Rep. 2017;7:453.
[2] Lin L, Hongsong Y, Yanni J, Deng B, Bai L, Kijlstra A et al. Genetic Variations of NLR family genes in Behcet’s Disease. Sci Rep. 2016;6:20098.
[3] Konè-Paut I, Sanchez E, Le Quellec A, Manna R, Touitou I. Autoinflammatory gene mutations in Behçet’s disease. Ann Rheum Dis. 2007;66:832-834.
[4] Yüksel S, Eren E, Hatemi G. Sahillioğlu AC, Gültekin Y, Demiröz D. Novel NLRP3/cryopyrin mutations and pro-inflammatory cytokine profiles in Behçet’s syndrome patients. Int Immunol. 2013;26:71-81.
[5] Gul A. Pathogenesis of Behçet's disease: autoinflammatory features and beyond. Semin Immunopathol. 2015;37(4):413-8.
[6] Takeuchi M, Kastner DL, Remmers EF. The immunogenetics of Behçet’s disease: A comprehensive review. J Autoimmun. 2015;64:137-148.
[7] Deng Y, Zhu W, Zhou X. Immune Regulatory Genes Are Major Genetic Factors to Behcet Disease: Systematic Review. Open Rheumatol J. 2018;12:70-85.
[8] Marotte H, Arnaud B, Diasparra J, Zrioual S, Miossec P. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor. Arthritis Rheum. 2008;58(5):1258-63.
[9] O'Rielly DD, Roslin NM, Beyene J, Pope A, Rahman P. TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. Pharmacogenomics J. 2009;9(3):161-7.
[10] Pavy S, Toonen EJ, Miceli-Richard C, Barrera P, van Riel PL, Criswell LA et al. Tumour necrosis factor alpha -308G->A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis. 2010;69(6):1022-8.
[11] Zeng Z, Duan Z, Zhang T, Wang S, Li G, Gao J et al. Association between tumor necrosis factor-α (TNF-α) promoter -308 G/A and response to TNF-α blockers in rheumatoid arthritis: a meta-analysis. Mod Rheumatol. 2013;23(3):489-95.
[12] Bek S, Bojesen AB, Nielsen JV, Sode J, Bank S, Vogel U et al. Systematic review and meta-analysis:pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis. Pharmacogenomics J. 2017;17(5):403-411.
[13] Aflatoonian M, Moghimi M, Akbarian-Bafghi MJ, Morovati-Sharifabad M, Jarahzadeh MH, Neamatzadeh H. Association of TNF- α-308G>A polymorphism with susceptibility to celiac disease: a systematic review and meta-analysis. Arq Gastroenterol. 2019;56(1):88-94.
[14] Al-Okaily F, Arfin M, Al-Rashidi S, Al-Balawi M, Al-Asmari A. Inflammation-related cytokine gene polymorphisms in Behçet's disease. J Inflamm Res. 2015;8:173-80.
[15] Badano I, Stietz SM, Schurr TG, Picconi AM, Fekete D, Quintero IM et al. Analysis of TNFalpha promoter SNPs and the risk of cervical cancer in urban populations of Posadas (Misiones, Argentina). J Clin Virol. 2012;53:54-59.
[16] Liang Y, Xu WD, Zhang M, Qiu LJ, Ni J, Wang XS et al. Meta-analysis of association between cytokine gene polymorphisms and Behcet's disease risk. Int J Rheum Dis. 2013;16(6):616-24.
[17] Wang L, Ma K, Wang Z, Mou Y, Ma L, Guo Y. Association between tumor necrosis factor alpha rs1800629 polymorphism and risk of cervical cancer. Int J Clin Exp Med. 2015;8(2):2108-17.
[18] Wang L, Qu G, Wu W, Tang X, Sun Y. Association between tumor necrosis factor-α-308G/A gene polymorphism and susceptibility to pre-eclampsia: An updated meta-analysis. Cytokine. 2018;111:278-286.
[19] Yang F, Wei K, Qin Z, Shao C, Shu Y, Shen H. Association between TNF-ɑ-308G/A polymorphism and esophageal cancer risk: An updated meta-analysis and trial sequential analysis. J Cancer. 2019;10(5):1086-1096.
[20] Zhang M, Xu WD, Wen PF, Liang Y, Liu J, Pan HF, et al. 2013. Polymorphisms in the tumor necrosis factor gene and susceptibility to Behcet's disease: an updated meta-analysis. Mol Vis. 2013;19:1913-24.
[21] Zhang Y, Cao Y, Xin L, Gao N, Liu B. Association between rs1800629 polymorphism in tumor necrosis factor-α gene and dilated cardiomyopathy susceptibility: Evidence from case-control studies. Medicine (Baltimore). 2018;97(50):e13386.
[22] Abdolmohammadi R, Bonyadi M. Polymorphisms of Promoter Region of TNF-α Gene in Iranian Azeri Turkish Patients with Behçet's Disease. J Korean Med Sci. 2017;32(1):33-37.
[23] Ateş A, Kinikli G, Düzgün N, Duman M. Lack of association of tumor necrosis factor-alpha gene polymorphisms with disease susceptibility and severity in Behçet's disease. Rheumatol Int. 2006;26(4):348-53.
[24] Ateş O, Dalyan L, Hatemi G, Hamuryudan V, Topal-Sarıkaya A. Analyses of functional IL10 and TNF-α genotypes in Behçet's syndrome. Mol Biol Rep. 2010;37(7):3637-41.
[25] Bonyadi M, Jahanafrooz Z, Esmaeili M, Kolahi S, Khabazi A, Ebrahimi AA et al. TNF-alpha gene polymorphisms in Iranian Azeri Turkish patients with Behcet's Disease. Rheumatol Int. 2009;30(2):285-9.
[26] Duymaz-Tozkir J, Gül A, Uyar FA, Ozbek U, Saruhan-Direskeneli G. Tumour necrosis factor-alpha gene promoter region -308 and -376 G-->A polymorphisms in Behçet's disease. Clin Exp Rheumatol. 2003;21(4):S15-8.
[27] Kamoun M, Chelbi H, Houman MH, Lacheb J, Hamzaoui K. Tumor necrosis factor gene polymorphisms in Tunisian patients with Behcet's disease. Hum Immunol. 2007;68(3):201-5.
[28] Lee EB, Kim JY, Lee YJ, Park MH, Song YW. TNF and TNF receptor polymorphisms in Korean Behcet's disease patients. Hum Immunol. 2003;64(6):614-20.
[29] Park K, Kim N, Nam J, Bang D, Lee ES. Association of TNFA promoter region haplotype in Behçet's Disease. J Korean Med Sci. 2006;21(4):596-601.
[30] Radouane A, Oudghiri M, Chakib A, Bennani S, Touitou I, Barat-Houari M. SNPs in the TNF-α gene promoter associated with Behcet's disease in Moroccan patients. Rheumatology (Oxford). 2012;51(9):1595-9.
[31] Storz K, Löffler J, Koch S, Vonthein R, Zouboulis CC, Fresko I et al. IL-6 receptor, IL-8 receptor and TNF-alpha238 (G/A) polymorphisms are not associated with Behçet's disease in patients of German or Turkish origin. Clin Exp Rheumatol. 2008;26:S103-6.
[32] Touma Z, Farra C, Hamdan A, Shamseddeen W, Uthman I, Hourani H et al. TNF polymorphisms in patients with Behçet disease: a meta-analysis. Arch Med Res. 2010;41(2):142-6.
[33] Weichsler B, Davatchi F, Mizushima Y, Hamza M, Dilsen N et al. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet. 1990. 335(8697):1078-1080.
[34] Krause I, Rose Y, Kaplan I, Milo G, Guedj D, Molad Y et al. Recurrent aphthous stomatitis in Behçet’s disease: clinical features and correlation with systemic disease expression and severity. J Oral Pathol Med. 1999;28:193-196.
[35] Gul A. Genetics of Behçet’s disease: lessons learned from genomewide association studies. Current Opinion in Rheumatology. 2014;26: 56-63.
[36] Khaib Dit Naib O, Aribi M, Idder A, Chiali A, Sairi H, Touitou I et al. Association Analysis of IL10, TNF-α, and IL23R-IL12RB2 SNPs with Behçet's Disease Risk in Western Algeria. Front Immunol. 2013;4:342.
[37] Kirino Y, Bertsias G, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E et al. Genome-wide association analysis identifies new susceptibility loci for Behçet’s disease and epistasis between HLA-B*51 and ERAP1. Nat Genet. 2013;45(2):202-207.
[38] Leccese P, Padula MC, Santospirito EV, Colucci R, Lascaro N, D'Angelo S. HLA-B*51 subtypes molecular analysis in a series of Italian patients with Behçet's syndrome. Joint Bone Spine. 2019;86(6):807-808.
[39] Ombrello MJ, Kastner DL, Remmers EF. Endoplasmic reticulum-associated amino-peptidase 1 and rheumatic disease: genetics. Curr Opin Rheumatol. 2015;27:349-356.
[40] Padula MC, Leccese P, Lascaro N, Carbone T, Gilio M, Padula AA et al. Genotyping of Italian patients with Behçet syndrome identified two novel ERAP1 polymorphisms using sequencing-based approach. Hum Immunol. 2019;80:335-338.